ESGO 2013

Dr Johan Menten talks to ecancer at the 2013 ESGO meeting about the clinical aspects of end of life care in gynecological cancer.

Dr Kumar talks to ecancer at the 2013 ESGO meeting about a study that looks at outcomes of patients with early stage ovarian endometroid carcinoma. The aims of the study were to determine prognostic factors and determine the impact of adjuvant treatment on survival in patients with early stage ovarian endometroid carcinoma. The study found that omission of adjuvant treatment could be considered in the majority of early stage ovarian endometroid carcinoma, except stage IC other and II, where irradiation may be of benefit.

Prof Denis Querleu talks to ecancer about the management of locally advanced cervical cancer at the 2013 ESGO meeting in Liverpool. Prof Querleu addresses a range of issues in treating cervical cancer including clinical trials, methods of surgery and adjuvant chemo-radiation. Also, discussed are topics covered in a session Prof Querleu chaired on selecting the correct surgical approach in patients with cervical cancer.

Dr Annette Hasenburg talks to ecancer at the 2013 ESGO meeting about the psychological and physical effects of living with cancer and life after treatment. Dr Hasenburg emphasises the need for more discussion between doctors and patients about the complexities of life after cancer and the changes to a patient’s personal life.

Prof Christian Marth talks to ecancer at the 2013 ESGO meeting in Liverpool about the organisation of clinical cancer trials in Europe and the European Network of Gynae-oncological Trial Groups (ENGOT). Prof Marth also talks about angiogenesis, which is an important component to driving the growth of ovarian cancer and two large randomised clinical trials that have demonstrated an improvement of progresion free survival by the addition of bevacizumab to chemotherapy in front-line therapy. The addition of bevacizumab is recommended for patients with advanced ovarian cancer with poor prognostic factors such as FIGO stage IIIB – IV.

Dr Mario Sideri talks to ecancer at the 2013 ESGO meeting about new methods of screening for cervical cancer.

Prof Eric Pujade Lauraine talks to ecancer at the 2013 ESGO meeting in Liverpool about the results of the ICON7 study. ICON7 is a phase III randomised trial that looks at standard chemotherapy with or without bevacizumab in advanced ovarian cancer and measures the quality of life of the outcomes.

Prof Bradley Monk talks to ecancer at the 2013 ESGO meeting in Liverpool about a phase III, randomised trial with pacitaxel plus trebanaib in recurrent ovarian cancer. Trebananib is an anti-angiogenesis peptibody that inhibits the binding of angiopoietin 1/2 to the Tie2 receptor. The trial reported that trebananib prolonged progression free survival by 52% and had an increased response rate from 30% to 38%.

Prof John Green talks to ecancer at the 2013 ESGO meeting about the increasing rate of incidence of endometrial cancer and treatment guidelines. One of the main causes of the recent increase in cases of endometrial cancer is obesity and while endometrial cancer is becoming more common, many patients are responding better to new treatments. This is a result of a better understanding of the disease's different classifications.

Prof John Green talks to ecancer about the development and scientific programme of the 2013 ESGO meeting; as well as, the increasing membership base of ESGO.

Prof David Cibula talks to ecancer at the 2013 ESGO meeting in Liverpool about the surgical aspects of treating cervical cancer. Prof Cibula looks at the new sentinel node approach in cervical cancer and relevance of detection of micrometastases; in addition, radical hysterectomy classification is also discussed and the establishment of a standard of treatment in the surgical field.

Prof Frederic Amant talks to ecancer at the 2013 ESGO meeting in Liverpool about a follow up study in children whose mother’s received chemotherapy during their pregnancy. The previous results from this study show that these children develop normally without any complications.